目前CRISPR/cas9基因编辑系统的应用和未来前景介导肝癌治疗的免疫检查点
Ling-Wu Tong1, Yong-Shan Hu1, Shi-Jing Yu1
1Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350108, People's Republic of China.
Nanotechnology
|July 4, 2024
概括
集群定期间隔的短平行体重复/CRISPR相关核酶9 (CRISPR/Cas9) 技术为增强肝癌免疫检查点治疗提供了一个有希望的策略. 这种方法旨在克服当前治疗的局限性,并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 基因编辑 基因编辑
背景情况:
- 肝癌是全球普遍存在的恶性瘤,死亡率很高.
- 免疫检查点疗法对肝癌有希望,但有效性有限,副作用有限.
- 现有的治疗方法需要进一步的研究,以改善患者的治疗结果.
研究的目的:
- 审查CRISPR/Cas9技术的基本原理及其在肝癌免疫治疗中的应用.
- 使用CRISPR/Cas9.9探索肝癌免疫检查点治疗的分子机制.
- 讨论基于CRISPR/Cas9的肝癌免疫疗法的未来临床潜力和挑战.
主要方法:
- 关于CRISPR/Cas9技术和肝癌免疫治疗的当前文献的综述.
- 对肝癌免疫检查点治疗背后的分子机制的分析.
- 探索CRISPR/Cas9在增强抗肝癌免疫反应中的作用.
主要成果:
- 克里斯普尔/Cas9技术为加强肝癌免疫检查点治疗提供了一种新的策略.
- 了解分子机制可以指导开发更有效的治疗方法.
- 克里斯普尔/Cas9有可能改善患者的预后,克服治疗抵抗.
结论:
- 基于CRISPR/Cas9的免疫疗法为治疗肝癌提供了一个强大的新途径.
- 需要进一步的研究来应对现有的挑战,并将这项技术转化为临床实践.
- 这种方法可以显著提高肝癌患者的生存率和生活质量.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.8K
08:14Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
Published on: October 3, 2019
12.2K
相关概念视频
01:59CRISPR
50.4K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
50.4K
02:53CRISPR and crRNAs
16.9K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
16.9K